The FDA hosted the Gastroenterology Regulatory Endpoints and the Advancement of Therapeutics VI (GREAT VI) Workshop on Celiac Disease - the second workshop ever held by the FDA for celiac disease.
Continue ReadingResearchers at Boston Children’s Hospital are evaluating access to gluten-free food prior to and during the COVID-19 pandemic. We invite anyone with celiac disease following a gluten-free diet to complete this 3-5 minute survey.
Continue ReadingPeriodically, the FDA hosts workshops to help researchers understand exactly what the FDA will be looking for (aka “endpoints”) when evaluating the efficacy of a proposed drug.
Continue ReadingResearchers at MassGeneral Hospital for Children have found substantial gut microbiome changes in the intestines of at-risk infants before celiac disease onset.
Continue ReadingZED1227, an experimental drug was found to be able to prevent intestinal damage in a preliminary trial of 163 adults with celiac disease.
Continue Reading
